Study on the clinical efficacy of dienogest in treating patients with adenomyosis-associated dysmenorrhea and its mechanism
Objective To investigate the clinical efficacy of dienogest in treating patients with adenomyosis-associated dysmenorrhea and its mechanism.Methods A total of 200 patients with dysmenorrhea in Hechi People's Hospital from January 2019 to December 2020 were divided into control group(n=100)and observation group(n=100)according to the random number table method.The control group was treated with gestrinone and the observation group was treated with dienogest,and both groups were treated continuously for 3 menstrual cycles.The menstrual volume,visual analogue score(VAS),uterine fibroid/adenomyosis symptoms(UFS)and quality of life(QOL)scores,and tumor necrosis factor-α(TNF-α)levels before and after treatment were compared between the two groups.Results After treatment,menstrual volume and VAS scores were significantly lower in both groups than those before treatment,and those in the observation group were lower than those in the control group(P<0.05).UFS scores were significantly lower and QOL scores were significantly higher in both groups after treatment than those before treatment,and UFS scores were lower and QOL scores were higher in the observation group than those in the control group(P<0.05).Serum TNF-α levels were significantly lower in both groups after treatment than those before treatment,and those in the observation group was lower than those in the control group(P<0.05).Conclusion Dienogest has definite efficacy in the treatment of adenomyosis-associated dysmenorrhea,and it can effectively improve the clinical symptoms and QOL of the patients.Its mechanism may be related to the regulation of the expression of TNF-α in serum.
万方数据
维普
